Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
8(88.9%)
Phase 3
1(11.1%)
9Total
N/A(8)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT03593369Not ApplicableUnknown

Assessment of the Evolution of Wound Biomarkers in Venous Leg Ulcers Treated With KLOX Biophotonic System

Role: lead

NCT03271164Not ApplicableCompleted

Evaluation of the Safety and Efficacy of FBPM10 System in the Treatment of Post-surgical Wounds

Role: lead

NCT02604251Not ApplicableCompleted

Evaluation of the KLOX BioPhotonic WoundGel System in the Treatment of Surgical Wounds

Role: lead

NCT03021811Not ApplicableCompleted

EUREKA Italy - Evaluation of Real-life Use of KLOX BioPhotonic System in Chronic Wounds Management

Role: lead

NCT02222506Not ApplicableCompleted

Safety Evaluation of the KLOX BioPhotonic System in Diabetic Foot Ulcers

Role: lead

NCT02325570Not ApplicableCompleted

Evaluation of the KLOX BioPhotonic OraLum Gel With a LED Curing Lamp in Moderate to Severe Chronic Periodontitis

Role: lead

NCT02222454Not ApplicableCompleted

Safety Evaluation of the KLOX BioPhotonic System in Stage II and III Pressure Ulcers

Role: lead

NCT02222467Not ApplicableCompleted

Safety Evaluation of the KLOX BioPhotonic System in Venous Leg Ulcers

Role: lead

NCT01584674Phase 3Completed

A Clinical Trial Evaluating the Safety and Efficacy of the KLOX Biophotonic System in Moderate to Severe Acne

Role: lead

All 9 trials loaded